Manufacturer Access as GLP-1 Moat
Numan
Direct manufacturer access is becoming the real moat in GLP-1 telehealth, because it determines who can actually keep patients on therapy when supply gets tight. In Europe, many providers still buy through wholesalers, which means inventory can disappear week to week and drug costs can jump. For a company like Numan, that turns supply into both a margin issue and a retention issue, because patients usually stay only if the prescribed drug is available every month.
-
US platforms are moving closer to drug makers. Ro integrated with NovoCare Pharmacy in April 2025 to offer Wegovy through the Ro app at $499 per month, and LifeMD markets branded Zepbound access tied to Lilly programs. That shortens the chain between prescriber and manufacturer.
-
European models are more mixed. Numan owns the digital clinic, clinicians, and pharmacy workflow, but the supply risk still sits upstream if branded GLP-1 stock has to be sourced through distributors rather than guaranteed manufacturer allocation. Yazen goes one step further removed, with prescriptions filled by partner pharmacies at retail market prices.
-
This is why US entrants matter beyond marketing spend. Hims agreed to acquire ZAVA in June 2025, giving it licensed operations across the UK, Germany, France, and Ireland, while bringing a playbook already built around scaled pharmacy fulfillment and pharma partnerships into Europe.
The next phase of European obesity telehealth will be shaped less by who has the best app and more by who locks in the cleanest drug supply. As shortages ease, wholesale dependence will matter less on availability and more on price. The winners will be the platforms that convert medication access into predictable monthly economics and lower churn.